Skip to main content
Log in

Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin

  • Case Report
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Summary

The HMG-CoA reductase inhibitor, lovastatin, is known to induce asymptomatic liver dysfunction in a few patients. We report the case of an adult who suffered from clinical hepatitis three months after the onset of lovastatin administration. Manifestations included asthenia, jaundice, and increased aminotransferase and alkaline phosphatase activities. Histologic examination showed centrilobular necrosis, centrilobular cholestasis, and infiltrates with mononuclear and polymorphonuclear cells, including eosinophils. Withdrawal of lovastatin was followed by complete normalization of liver tests within two months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Grundy SM: HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319:24–31, 1988

    PubMed  Google Scholar 

  2. Oates JA, Wood AJ: HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319:24–33, 1988

    PubMed  Google Scholar 

  3. Stein EA, Lamkin GE, Bewley DZ: Lovastatin alone and in combination for treatment of primary hypercholesterolemia. Prog Clin Biol 255:281–293, 1988

    Google Scholar 

  4. Lovastatin Study Groups I through IV: Lovastatin 5-year safety and efficacy study. Arch Intern Med 153:1079–1087, 1993

    Google Scholar 

  5. McQueen MJ: Cholestatic jaundice associated with lovastatin therapy. Can Med Assoc J 142:841–842, 1990

    Google Scholar 

  6. Raveh D, Israeli A, Arnon R, Eisenberg S: Lovastatin-induced hepatitis. Isr J Med Sci 28:101–102, 1992

    PubMed  Google Scholar 

  7. Mantell G, Burke MT, Staggers J: Extended clinical safety profile of lovastatin. Am J Cardiol 66:11B-15B, 1990

    PubMed  Google Scholar 

  8. Sarachek NS, London RL, Matulewicz TJ: Diltiazem and granulomatous hepatitis. Gastroenterology 88:1260–1262, 1985

    PubMed  Google Scholar 

  9. Asorey A, Garcia-Alegria JJ, Garcia-Garcia I, Jimenez LC, Blasquez ML: Cholestatic hepatitis from diltiazem. Eur J Intern Med 2:245–246, 1992

    Google Scholar 

  10. Ballare M, Campani M, Catania E, Bordin G, Zaccala G, Monteverde A: Acute cholestatic hepatitis during simvastatin administration. Recenti Prog Med 82:233–235, 1991

    PubMed  Google Scholar 

  11. Mabuchi H, Haba T, Tatami R, Miyamoto S, Sakai Y, Wakasugi T, et al: Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. N Engl J Med 305:478–482, 1981

    PubMed  Google Scholar 

  12. Komai T, Kawai K, Tokui T, Tokui Y, Kuroiwa C, Shigehara E, et al: Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys. Eur J Drug Metab Pharmacokinet 17:103–113, 1992

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grimbert, S., Pessayre, D., Degott, C. et al. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin. Digest Dis Sci 39, 2032–2033 (1994). https://doi.org/10.1007/BF02088142

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02088142

Key words

Navigation